A transmembrane amino acid in the GABAA receptor β2 subunit critical for the actions of alcohols and anesthetics.
Alcohols and inhaled anesthetics enhance the function of GABA(A) receptors containing α, β, and γ subunits. Molecular analysis has focused on the role of the α subunits; however, there is evidence that the β subunits may also be important. The goal of our study was to determine whether Asn265, which is homologous to the site implicated in the α subunit (Ser270), contributes to an alcohol and volatile anesthetic binding site in the GABA(A) receptor β(2) subunit. We substituted cysteine for Asn265 and exposed the mutant to the sulfhydryl-specific reagent octyl methanethiosulfonate (OMTS). We used two-electrode voltage-clamp electrophysiology in Xenopus laevis oocytes and found that, after OMTS application, GABA-induced currents were irreversibly potentiated in mutant α(1)β(2)(N265C)γ(2S) receptors [but not α(1)β(2)(I264C)γ(2S)], presumably because of the covalent linking of octanethiol to the thiol group in the substituted cysteine. It is noteworthy that this effect was blocked when OMTS was applied in the presence of octanol. We found that potentiation by butanol, octanol, or isoflurane in the N265C mutant was nearly abolished after the application of OMTS, suggesting that an alcohol and volatile anesthetic binding site at position 265 of the β(2) subunit was irreversibly occupied by octanethiol and consequently prevented butanol or isoflurane from binding and producing their effects. OMTS did not affect modulation or direct activation by pentobarbital, but there was a partial reduction of allosteric modulation by flunitrazepam and alphaxalone in mutant α(1)β(2)(N265C)γ(2S) receptors after OMTS was applied. Our findings provide evidence that Asn265 may contribute to an alcohol and anesthetic binding site.
McCracken
Mandy L
ML
Waggoner Center for Alcohol and Addiction Research, University of Texas, Austin, Texas 78712, USA.
Borghese
Cecilia M
CM
Trudell
James R
JR
Harris
R Adron
RA
D020001:1-Butanol / Q000378:metabolism / Q000494:pharmacology; D020003:1-Octanol / Q000378:metabolism / Q000494:pharmacology; D000438:Alcohols / Q000378:metabolism / Q000494:pharmacology*; D019943:Amino Acid Substitution / Q000502:physiology; D000777:Anesthetics / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001216:Asparagine / Q000502:physiology*; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D003545:Cysteine / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D000431:Ethanol / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology; D007530:Isoflurane / Q000378:metabolism / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D018075:RNA, Complementary / Q000235:genetics; D051381:Rats; D011963:Receptors, GABA-A / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D013886:Thiosulfonic Acids / Q000378:metabolism / Q000494:pharmacology; D014982:Xenopus laevis; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D000438:Alcohols; D000777:Anesthetics; C495710:GABRB2 protein, human; C546242:Gabra1 protein, rat; C546281:Gabrg2 protein, rat; D018075:RNA, Complementary; D011963:Receptors, GABA-A; D013886:Thiosulfonic Acids; D000431:Ethanol; D005680:gamma-Aminobutyric Acid; D001216:Asparagine; D020001:1-Butanol; D007530:Isoflurane; D003545:Cysteine; D020003:1-Octanol
Neurosci Lett. 2007 Apr 18;416(3):275-8
17350761
J Biol Chem. 2005 Jan 7;280(1):308-16
15522868
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6504-9
9600996
J Neurosci. 2001 Jul 15;21(14):4977-86
11438573
Alcohol Clin Exp Res. 1999 Oct;23(10):1563-70
10549986
J Neurosci. 1997 Apr 15;17(8):2728-37
9092594
J Biol Chem. 2010 Mar 19;285(12):8615-20
20083606
ACS Chem Neurosci. 2010 Jul;1(7):482
21326622
Nature. 2006 Nov 23;444(7118):486-9
17108970
Br J Pharmacol. 1999 May;127(2):377-82
10385236
Neuropharmacology. 2002 Mar;42(3):337-45
11897112
J Biol Chem. 1998 Feb 6;273(6):3314-9
9452448
Neuropharmacology. 2009 Jan;56(1):141-8
18760291
Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):267-82
9303562
Curr Top Med Chem. 2002 Aug;2(8):795-816
12171572
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11031-6
9380754
J Biol Chem. 2009 Oct 2;284(40):27304-14
19656948
Annu Rev Pharmacol Toxicol. 2001;41:23-51
11264449
Trends Neurosci. 1995 Mar;18(3):121-7
7754520
Mol Neurobiol. 1998 Aug;18(1):35-86
9824848
Nat Rev Neurosci. 2008 May;9(5):370-86
18425091
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6275-80
20308576
Nature. 2003 Jun 26;423(6943):949-55
12827192
J Biol Chem. 2008 May 30;283(22):15250-7
18387955
FASEB J. 2003 Feb;17(2):250-2
12475885
Nature. 1997 Sep 25;389(6649):385-9
9311780
Anesth Analg. 2005 Aug;101(2):412-418
16037154
J Mol Graph Model. 2004 Sep;23(1):39-49
15331052
J Pharmacol Exp Ther. 2003 Oct;307(1):42-52
14500778
Nature. 2009 Jan 1;457(7225):111-4
18987633
J Biol Chem. 2004 Aug 6;279(32):33919-27
15169788
J Neurochem. 2007 Sep;102(6):2097-2109
17561937
Mol Pharmacol. 2004 Jan;65(1):68-76
14722238
J Neurosci. 2003 Sep 17;23(24):8608-17
13679430
J Gen Physiol. 1996 Feb;107(2):195-205
8833341
J Neurosci. 2001 Mar 15;21(6):RC136
11245705
Pharmacol Rev. 2008 Sep;60(3):243-60
18790874
J Biol Chem. 2003 Apr 11;278(15):13166-72
12556472
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9305-10
10908659